Alessandra M Passarotti1, John A Sweeney, Mani N Pavuluri. 1. Pediatric Brain Research and Intervention Center, Institute for Juvenile Research, University of Illinois Medical Center at Chicago, Chicago, IL 60608, USA. apassarotti@psych.uic.edu
Abstract
RATIONALE: Neural deficits at the interface of affect and cognition may improve with pharmacotherapy in pediatric bipolar disorder (PBD). OBJECTIVES: We examined lamotrigine treatment impact on the neural interface of working memory and affect in PBD. METHODS: Un-medicated, acutely ill, patients with mania and hypomania (n = 17), and healthy controls (HC; n = 13; mean age = 13.36 ± 2.55) performed an affective two-back functional magnetic resonance imaging task with blocks of angry vs neutral faces (i.e., angry face condition) or happy vs neutral faces (i.e., happy face condition) before treatment and at follow-up, after 8-week treatment with second-generation antipsychotics followed by 6 weeks of lamotrigine monotherapy. RESULTS: At baseline, for the angry face condition, PBD, relative to HC, showed reduced activation in the left ventrolateral prefrontal cortex (VLPFC) and right caudate; for the happy face condition, PBD showed increased activation in bilateral PFC and right amygdala and middle temporal gyrus. Post-treatment, PBD showed greater activation in right amygdala relative to HC for both conditions. Patients, relative to HC, exhibited greater changes over time in the right VLPFC and amygdala, left subgenual anterior cingulate cortex and left caudate for the angry face condition, and in right middle temporal gyrus for the happy face condition. CONCLUSIONS: Pharmacotherapy resulted in symptom improvement and normalization of higher cortical emotional and cognitive regions in patients relative to HC, suggesting that the VLPFC dysfunction may be state-specific in PBD. Amygdala was overactive in PBD, relative to HC, regardless of reduction in manic symptoms, and may be a trait marker of PBD.
RATIONALE: Neural deficits at the interface of affect and cognition may improve with pharmacotherapy in pediatric bipolar disorder (PBD). OBJECTIVES: We examined lamotrigine treatment impact on the neural interface of working memory and affect in PBD. METHODS: Un-medicated, acutely ill, patients with mania and hypomania (n = 17), and healthy controls (HC; n = 13; mean age = 13.36 ± 2.55) performed an affective two-back functional magnetic resonance imaging task with blocks of angry vs neutral faces (i.e., angry face condition) or happy vs neutral faces (i.e., happy face condition) before treatment and at follow-up, after 8-week treatment with second-generation antipsychotics followed by 6 weeks of lamotrigine monotherapy. RESULTS: At baseline, for the angry face condition, PBD, relative to HC, showed reduced activation in the left ventrolateral prefrontal cortex (VLPFC) and right caudate; for the happy face condition, PBD showed increased activation in bilateral PFC and right amygdala and middle temporal gyrus. Post-treatment, PBD showed greater activation in right amygdala relative to HC for both conditions. Patients, relative to HC, exhibited greater changes over time in the right VLPFC and amygdala, left subgenual anterior cingulate cortex and left caudate for the angry face condition, and in right middle temporal gyrus for the happy face condition. CONCLUSIONS: Pharmacotherapy resulted in symptom improvement and normalization of higher cortical emotional and cognitive regions in patients relative to HC, suggesting that the VLPFC dysfunction may be state-specific in PBD. Amygdala was overactive in PBD, relative to HC, regardless of reduction in manic symptoms, and may be a trait marker of PBD.
Authors: Brendan A Rich; Deborah T Vinton; Roxann Roberson-Nay; Rebecca E Hommer; Lisa H Berghorst; Erin B McClure; Stephen J Fromm; Daniel S Pine; Ellen Leibenluft Journal: Proc Natl Acad Sci U S A Date: 2006-05-30 Impact factor: 11.205
Authors: Roxann Roberson-Nay; Erin B McClure; Christopher S Monk; Eric E Nelson; Amanda E Guyer; Stephen J Fromm; Dennis S Charney; Ellen Leibenluft; James Blair; Monique Ernst; Daniel S Pine Journal: Biol Psychiatry Date: 2006-04-17 Impact factor: 13.382
Authors: Mani N Pavuluri; James A Ellis; Ezra Wegbreit; Alessandra M Passarotti; Michael C Stevens Journal: Behav Brain Res Date: 2011-10-08 Impact factor: 3.332
Authors: Wan-Ling Tseng; Laura A Thomas; Elizabeth Harkins; Daniel S Pine; Ellen Leibenluft; Melissa A Brotman Journal: Soc Cogn Affect Neurosci Date: 2015-07-02 Impact factor: 3.436
Authors: Ahmed Abou Elseoud; Juuso Nissilä; Anu Liettu; Jukka Remes; Jari Jokelainen; Timo Takala; Antti Aunio; Tuomo Starck; Juha Nikkinen; Hannu Koponen; Yu-Feng Zang; Osmo Tervonen; Markku Timonen; Vesa Kiviniemi Journal: Hum Brain Mapp Date: 2012-09-15 Impact factor: 5.038
Authors: Mani N Pavuluri; Alessandra M Passarotti; Jacklynn M Fitzgerald; Ezra Wegbreit; John A Sweeney Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: Wenjing Zhang; Yuan Xiao; Huaiqiang Sun; L Rodrigo Patino; Maxwell J Tallman; Wade A Weber; Caleb M Adler; Christina Klein; Jeffrey R Strawn; Fabiano G Nery; Qiyong Gong; John A Sweeney; Su Lui; Melissa P DelBello Journal: Neuropsychopharmacology Date: 2018-06-18 Impact factor: 7.853
Authors: Amy S Garrett; Allan L Reiss; Meghan E Howe; Ryan G Kelley; Manpreet K Singh; Nancy E Adleman; Asya Karchemskiy; Kiki D Chang Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-06-27 Impact factor: 8.829